ClinicalTrials.gg
Enrolling by invitationNCT07072676Risk of fallUpdated Jul 18, 2025

The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period.

An interventional study of Assistive gait devices combined with physiotherapy in Inclusion Body Myositis, Myotonic Dystrophy 1 and Myotonic Dystrophy 2, sponsored by LMU Klinikum. Enrolling by invitation at 1 site in Germany. Open to participants aged 65 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-07-18.

Sponsored by LMU Klinikum · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
65 Years to 65 Years
Sex
All
01

Study summary

The planned project is an intervention study to assess the risk of falling after adaptation of an assistive gait devices in patients with the following neuromuscular diseases: Inclusion body myositis, myotonic dystrophy, limb girdle and facioscapulohumeral muscular dystrophies, Pompe disease, Lambert-Eaton syndrome, myasthenia gravis, spinal muscular atrophy, Guillain-Barré syndrome, chronic inflammatory demyelinating polyradiculoneuropathy, Friedreich's ataxia and hereditary motor and sensory neuropathy.

The primary aim is to assess the risk of falling after a suitable assistive gait device has been provided with an adaptation phase through training. The data should help to improve the provision of aids for patients with neuromuscular diseases. This should have a positive effect on the risk of falling and thus improve quality of life and reduce mortality and morbidity. To achieve these goals, a one-week intervention with training sessions on handling, balance and coordination as well as fall prevention will becarried out after the patient has been fitted with a suitable assistive gait device.

The interventions will be embedded in the inpatient rehabilitation programme. The functional gait and balance tests 'Timed Up and Go', '10 metre walk test', '6-minute walk test' and 'Dynamic Gait Index' will be recorded additionally.

The Falls Efficacy Scale International questionnaire will be utilised to evaluate the risk of falling, while the Quebec User Evaluation of Satisfaction with Assistive Technology questionnaire will be employed to ascertain satisfaction with the assistive devices. The study is scheduled to run for a period of 14 days, during which participants will undergo three functional walking and balance tests. As part of the inpatient rehabilitation programme, participants will undergo a week-long period of rehabilitation without assistive technology, followed by a subsequent week of rehabilitation with adapted assistive technology.

02

Conditions studied

  • Inclusion Body Myositis
  • Myotonic Dystrophy 1
  • Myotonic Dystrophy 2
  • Facio-Scapulo-Humeral Dystrophy
  • Limb Girdle Muscular Dystrophies
  • Pompe Disease (Infantile-Onset)
  • Myasthaenia Gravis
  • Lambert Eaton (LEMS)
  • Spinal Muscular Atrophy (SMA)
  • Guillain Barré Syndrome
  • Chronic Inflammatory Demyelinating Polyneuropathy
  • Friedreich Ataxia
  • Hereditary Motor and Sensory Neuropathies

Keywords

  • assistive gait device, neuromuscular diseases
03

In context

Myositis, Inclusion Body

65 studies on the registry are indexed under Myositis, Inclusion Body; 10 are open to participants now.

This study's planned enrollment of 30 is close to the median of 30 across 42 interventional studies indexed under Myositis, Inclusion Body.

Browse Myositis, Inclusion Body studies →

Lead sponsor

LMU Klinikum is the lead sponsor of 53 studies on the registry; 20 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The Patients with sufficient cognitive and communicative abilities,
  • The Patients with confirmed by the genetic report and/or the final clinical diagnosis.

Exclusion criteria

Exclusion Criteria:

  • The Patients scored more than 23 points on the falls efficacy Scale-International
  • The Patients are unable to walk at least ten metres without assistance,
  • The patient had knee, hip or back surgery in the last three months.
  • Patients suffering from polyneuropathy without a diagnosis of inflammatory neuropathy.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • No intervention
    Pre-intervention period

    One week without therapy with asssisitive gait devices. During this week, patients undergoing inpatient rehabilitation receive standard therapy for neuromuscular disorders.

  • Experimental
    Intervention period

    One week therapy with assisitve gait devices.

    Device: Assistive gait devices combined with physiotherapy

Interventions

  • DeviceAssistive gait devices combined with physiotherapy

    During the intervenation week, the patient undergoes 12 hours/week of gait training, fall prevention, balance group and physiotherapy as part of their inpatient rehabilitation programme. The individual sessions last 30 minutes each.

06

What researchers measure

Primary outcomes

  1. 6 Minute Walk Test

    The aim of this test is to walk as far as possible for 6 minutes.

    Time frame: At Day 1, end of pre-intervention period Day 7, and at the end of post-intervation period Day 14.

  2. Timed Up and Go (TUG)

    The TUG test measures the time it takes to stand up from a chair, walk three metres, turn around and sit back down on the same chair.

    Time frame: At Day 1, end of pre-intervention period Day 7, and at the end of post-intervation period Day 14.

  3. 10 meter walk test

    Walking at maximum speed is measured in a long, flat-surface corridor of 10 meters, with a standing start and a "flying" finish 2.5 meters beyond the 10-meter mark.

    Time frame: At Day 1, end of pre-intervention period Day 7, and at the end of post-intervation period Day 14.

  4. Dynamic Gait Index

    Dynamic Gait Index tests the ability of the participant to maintain walking balance while responding to different task demands, through various dynamic conditions. It is a useful test in individuals with vestibular and balance problems and those at risk of falls.

    Time frame: At Day 1, end of pre-intervention period Day 7, and at the end of post-intervation period Day 14.

Secondary outcomes

  1. The Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST 2.0)

    The QUEST 2.0 evaluates a patient's satisfaction with various assistive technologies.

    Time frame: At the end of post-intervention period, Day 14.

07

Study locations

1 site
  • Medical Park, Bad Feilnbach, Reithofpark
    Bad Feilnbach, 53075, Germany
08

References and documents

Publications

  • Dias N, Kempen GI, Todd CJ, Beyer N, Freiberger E, Piot-Ziegler C, Yardley L, Hauer K. [The German version of the Falls Efficacy Scale-International Version (FES-I)]. Z Gerontol Geriatr. 2006 Aug;39(4):297-300. doi: 10.1007/s00391-006-0400-8. German. PubMed 16900450 ↗
  • Waterval NFJ, Brehm MA, Altmann VC, Koopman FS, Den Boer JJ, Harlaar J, Nollet F. Stiffness-Optimized Ankle-Foot Orthoses Improve Walking Energy Cost Compared to Conventional Orthoses in Neuromuscular Disorders: A Prospective Uncontrolled Intervention Study. IEEE Trans Neural Syst Rehabil Eng. 2020 Oct;28(10):2296-2304. doi: 10.1109/TNSRE.2020.3018786. Epub 2020 Aug 24. PubMed 32833637 ↗
  • Ounpuu S, Garibay E, Acsadi G, Brimacombe M, Pierz K. The impact of orthoses on gait in children with Charcot-Marie-Tooth disease. Gait Posture. 2021 Mar;85:198-204. doi: 10.1016/j.gaitpost.2021.02.005. Epub 2021 Feb 12. PubMed 33610823 ↗
  • Mijic M, Wirner-Piotrowski C, Jung A, Gutschmidt K, Arndt M, Garcia-Angarita N, Wenninger S, Young P, Schoser B. The assistive gait devices and their implementation in activities of daily living for patients with neuromuscular disease: A systematic review and meta-analysis. J Neuromuscul Dis. 2026 Jan;13(1):53-76. doi: 10.1177/22143602241289216. Epub 2024 Dec 8. PubMed 39973408 ↗
  • Dharmadasa T, Matamala JM, Huynh W, Zoing MC, Kiernan MC. Chapter 22 - Motor neurone disease. In: Day BL, Lord SRBT-H of CN, editors. Balanc. Gait, Falls, vol. 159, Elsevier; 2018, p. 345-57. https://doi.org/https://doi.org/10.1016/B978-0-444-63916-5.00022-7
  • Atalaia A, Thompson R, Corvo A, Carmody L, Piscia D, Matalonga L, Macaya A, Lochmuller A, Fontaine B, Zurek B, Hernandez-Ferrer C, Reinhard C, Gomez-Andres D, Desaphy JF, Schon K, Lohmann K, Jennings MJ, Synofzik M, Riess O, Yaou RB, Evangelista T, Ratnaike T, Bros-Facer V, Gumus G, Horvath R, Chinnery P, Laurie S, Graessner H, Robinson P, Lochmuller H, Beltran S, Bonne G. A guide to writing systematic reviews of rare disease treatments to generate FAIR-compliant datasets: building a Treatabolome. Orphanet J Rare Dis. 2020 Aug 12;15(1):206. doi: 10.1186/s13023-020-01493-7. PubMed 32787960 ↗

Related links

Individual participant data

Plan to share: No — In accordance with the guidelines of the Ethics Committee.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2025; primary completion for May 2027, 20 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2025
First posted
Jul 18, 2025
StartEst.
Sep 1, 2025
Primary completionEst.
May 1, 2027
CompletionEst.
Aug 1, 2028
Last update
Jul 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07072676
Lead sponsor
LMU Klinikum
Responsible party
Marko Mijic (Principal Investigator, LMU Klinikum) — Principal investigator
First posted
Jul 18, 2025
Start date
Sep 1, 2025 (estimated)
Primary completion
May 1, 2027 (estimated)
Completion
Aug 1, 2028 (estimated)
Last update
Jul 18, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion